Perspective Therapeutics (CATX) Shares Outstanding (Weighted Average) (2010 - 2026)

Perspective Therapeutics recorded quarterly Shares Outstanding (Weighted Average) of $103.6 million in Q1 2026, up 30487.37% quarter-over-quarter from $338715.0 in Q4 2025, and up 43.18% year-over-year from $72.4 million in Q1 2025.

Perspective Therapeutics' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $103.6 million for Q1 2026.

  • In Q1 2026, Shares Outstanding (Weighted Average) rose 43.18% year-over-year to $103.6 million; the TTM figure through Mar 2026 stood at $103.6 million (up 43.18% YoY), while the FY2025 annual figure was $338715.0, down 99.47% from the prior year.
  • Shares Outstanding (Weighted Average) came in at $103.6 million for Q1 2026 at Perspective Therapeutics, up from $338715.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $228.6 million in Q1 2023 to a low of $264573.0 in Q4 2022.
  • A 5-year average of $75.1 million and a median of $70.6 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
  • Across the five-year window, Shares Outstanding (Weighted Average) sank 99.81% in 2022 and surged 11083.67% in 2024, its largest moves.
  • Perspective Therapeutics' Shares Outstanding (Weighted Average) stood at $264573.0 in 2022, then jumped by 117.73% to $576063.0 in 2023, then soared by 11083.67% to $64.4 million in 2024, then tumbled by 99.47% to $338715.0 in 2025, then jumped by 30487.37% to $103.6 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $103.6 million, $338715.0, and $74.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.74 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 382.90 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 1.28 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 1.48 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 579.20 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 385.10 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 456.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 98.20 Mn
10 Perspective Therapeutics 380.23 Mn 380.23 Mn - 103.60 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 103.60 Mn
Dec 31, 2025 338,715.00
Sep 30, 2025 74.30 Mn
Jun 30, 2025 73.30 Mn
Mar 31, 2025 72.36 Mn
Dec 31, 2024 64.43 Mn
Sep 30, 2024 70.63 Mn
Jun 30, 2024 58.08 Mn
Mar 31, 2024 49.51 Mn
Dec 31, 2023 576,063.00
Sep 30, 2023 26.32 Mn
Jun 30, 2023 28.00 Mn
Mar 31, 2023 228.59 Mn
Dec 31, 2022 264,573.00
Sep 30, 2022 142.07 Mn
Jun 30, 2022 141.99 Mn
Mar 31, 2022 142.04 Mn
Dec 31, 2021 141.96 Mn
Sep 30, 2021 141.92 Mn
Jun 30, 2021 2.65 Mn
Mar 31, 2021 122.57 Mn
Dec 31, 2020 83.05 Mn
Sep 30, 2020 68.90 Mn
Jun 30, 2020 67.60 Mn
Mar 31, 2020 67.56 Mn
Dec 31, 2019 67.39 Mn
Sep 30, 2019 67.39 Mn
Jun 30, 2019 6.08 Mn
Mar 31, 2019 67.33 Mn
Dec 31, 2018 67.33 Mn
Sep 30, 2018 66.15 Mn
Jun 30, 2018 250,000.00
Mar 31, 2018 55.10 Mn
Dec 31, 2017 55.06 Mn
Sep 30, 2017 55.02 Mn
Jun 30, 2017 55.02 Mn
Mar 31, 2017 55.02 Mn
Dec 31, 2016 55.02 Mn
Sep 30, 2016 55.01 Mn
Jun 30, 2016 230,087.00
Mar 31, 2016 55.02 Mn
Dec 31, 2015 55.01 Mn
Sep 30, 2015 55.01 Mn
Jun 30, 2015 385,800.00
Mar 31, 2015 54.88 Mn
Dec 31, 2014 54.88 Mn
Sep 30, 2014 54.87 Mn
Jun 30, 2014 444,747.00
Mar 31, 2014 42.51 Mn
Dec 31, 2013 38.42 Mn
Sep 30, 2013 35.92 Mn
Jun 30, 2013 1.96 Mn
Mar 31, 2013 34.36 Mn
Dec 31, 2012 650,003.00
Sep 30, 2012 33.87 Mn
Jun 30, 2012 1.96 Mn
Mar 31, 2012 28.13 Mn
Dec 31, 2011 27.54 Mn
Sep 30, 2011 26.49 Mn
Jun 30, 2011 3.82 Mn
Mar 31, 2011 26.01 Mn
Dec 31, 2010 25.07 Mn
Sep 30, 2010 23.05 Mn